Robert Byrum, MD
Pulmonary Disease · Greensboro, NCNPI 1487620654
Payments from drug & device makers
Across 185 payments — averaging $96.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- Johnson & Johnson$1K
- Covidien LP$850
- GSK$498
- AstraZeneca$373
- Actelion Pharmaceuticals US, Inc.$182
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$8505%
- Travel & lodging$2,40514%
- Food & beverage$3,54520%
- Education$11,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 27 | $12,962 |
| Johnson & Johnson | 5 | $1,354 |
| Covidien LP | 2 | $850 |
| GSK | 33 | $498 |
| AstraZeneca | 26 | $373 |
| Actelion Pharmaceuticals US, Inc. | 10 | $182 |
| Merck | 7 | $143 |
| Galvanize Therapeutics, Inc | 1 | $130 |
| Auris Health, Inc. | 2 | $128 |
| Inogen, Inc. | 13 | $127 |
| Novartis | 9 | $123 |
| United Therapeutics Corporation | 6 | $117 |
| Grifols USA, LLC | 5 | $107 |
| Boehringer Ingelheim | 5 | $104 |
| Sanofi | 4 | $82 |
| Insmed, Inc. | 5 | $79 |
| Amgen | 3 | $60 |
| AbbVie(2 entities) | 3 | $42 |
| Mylan Specialty L.p. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Viatris Specialty LLC | 2 | $35 |
| Pfizer | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Verona Pharma, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Shionogi Inc | 1 | $17 |
| Avanos Medical | 1 | $17 |
| Quidel Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,170
- ION$3,000
- MONARCH$1,442
- superDimension$850
- ALIYA SYSTEM$130
How this compares
$17,800 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 246 | $181,941 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 283 | $162,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 202 | $144,243 |
| XolairOmalizumab | 24 | $81,457 |
| Spiriva RespimatTiotropium Bromide | 69 | $47,830 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $36,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $34,366 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $32,172 |
| EliquisApixaban | 43 | $24,665 |
| Spiriva HandihalerTiotropium Bromide | 30 | $17,084 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 33 | $16,566 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $16,451 |
| DuleraMometasone/Formoterol | 38 | $16,060 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 432 | $11,481 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $9,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Daliresp | $373 | $244,353413 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $498 | $231,597371 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $104 | $220,449366 claims |
| PfizerEliquis | $32 | $24,66543 claims |
| MerckDulera | $143 | $16,06038 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $18 | $72737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Greensboro
- Murali RamaswamyGreensboro$2M
- Michael WertGreensboro$412K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.